Cargando…

Is fixed short-course antimicrobial therapy justified for patients who are critically ill with intra-abdominal infections?

A long-course antibiotic therapy increases the risk of antibiotic resistance. A 7- to 14-day duration of therapy has been traditionally adopted in patients with intra-abdominal infections (IAIs). Prophylactic antibiotic use is warranted in uncomplicated IAIs, in which the infection involves a single...

Descripción completa

Detalles Bibliográficos
Autores principales: Takesue, Yoshio, Uchino, Motoi, Ikeuchi, Hiroki, Ueda, Takashi, Nakajima, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japan Society of Coloproctology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752122/
https://www.ncbi.nlm.nih.gov/pubmed/31559368
http://dx.doi.org/10.23922/jarc.2019-001
_version_ 1783452736864387072
author Takesue, Yoshio
Uchino, Motoi
Ikeuchi, Hiroki
Ueda, Takashi
Nakajima, Kazuhiko
author_facet Takesue, Yoshio
Uchino, Motoi
Ikeuchi, Hiroki
Ueda, Takashi
Nakajima, Kazuhiko
author_sort Takesue, Yoshio
collection PubMed
description A long-course antibiotic therapy increases the risk of antibiotic resistance. A 7- to 14-day duration of therapy has been traditionally adopted in patients with intra-abdominal infections (IAIs). Prophylactic antibiotic use is warranted in uncomplicated IAIs, in which the infection involves a single organ, and the source of the infection is completely eradicated by a surgical procedure. A large, randomized clinical trial of the treatment of complicated IAIs recently demonstrated that a fixed 4-day course of antibiotic therapy was as effective as a long-course therapy in patients who underwent adequate source control. Considering the poor prognosis and lack of clear evidence available for shortening the duration of antibiotic therapy in patients who are critically ill or those with ongoing signs of sepsis, the duration of therapy for complicated IAIs should be individually determined according to the clinical course. Limiting therapy to no more than 7 days seems to be warranted in patients who are critically ill with a good clinical response.
format Online
Article
Text
id pubmed-6752122
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher The Japan Society of Coloproctology
record_format MEDLINE/PubMed
spelling pubmed-67521222019-09-26 Is fixed short-course antimicrobial therapy justified for patients who are critically ill with intra-abdominal infections? Takesue, Yoshio Uchino, Motoi Ikeuchi, Hiroki Ueda, Takashi Nakajima, Kazuhiko J Anus Rectum Colon Review Article A long-course antibiotic therapy increases the risk of antibiotic resistance. A 7- to 14-day duration of therapy has been traditionally adopted in patients with intra-abdominal infections (IAIs). Prophylactic antibiotic use is warranted in uncomplicated IAIs, in which the infection involves a single organ, and the source of the infection is completely eradicated by a surgical procedure. A large, randomized clinical trial of the treatment of complicated IAIs recently demonstrated that a fixed 4-day course of antibiotic therapy was as effective as a long-course therapy in patients who underwent adequate source control. Considering the poor prognosis and lack of clear evidence available for shortening the duration of antibiotic therapy in patients who are critically ill or those with ongoing signs of sepsis, the duration of therapy for complicated IAIs should be individually determined according to the clinical course. Limiting therapy to no more than 7 days seems to be warranted in patients who are critically ill with a good clinical response. The Japan Society of Coloproctology 2019-04-25 /pmc/articles/PMC6752122/ /pubmed/31559368 http://dx.doi.org/10.23922/jarc.2019-001 Text en Copyright © 2019 by The Japan Society of Coloproctology https://creativecommons.org/licenses/by-nc-nd/4.0/ Journal of the Anus, Rectum and Colon is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Takesue, Yoshio
Uchino, Motoi
Ikeuchi, Hiroki
Ueda, Takashi
Nakajima, Kazuhiko
Is fixed short-course antimicrobial therapy justified for patients who are critically ill with intra-abdominal infections?
title Is fixed short-course antimicrobial therapy justified for patients who are critically ill with intra-abdominal infections?
title_full Is fixed short-course antimicrobial therapy justified for patients who are critically ill with intra-abdominal infections?
title_fullStr Is fixed short-course antimicrobial therapy justified for patients who are critically ill with intra-abdominal infections?
title_full_unstemmed Is fixed short-course antimicrobial therapy justified for patients who are critically ill with intra-abdominal infections?
title_short Is fixed short-course antimicrobial therapy justified for patients who are critically ill with intra-abdominal infections?
title_sort is fixed short-course antimicrobial therapy justified for patients who are critically ill with intra-abdominal infections?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752122/
https://www.ncbi.nlm.nih.gov/pubmed/31559368
http://dx.doi.org/10.23922/jarc.2019-001
work_keys_str_mv AT takesueyoshio isfixedshortcourseantimicrobialtherapyjustifiedforpatientswhoarecriticallyillwithintraabdominalinfections
AT uchinomotoi isfixedshortcourseantimicrobialtherapyjustifiedforpatientswhoarecriticallyillwithintraabdominalinfections
AT ikeuchihiroki isfixedshortcourseantimicrobialtherapyjustifiedforpatientswhoarecriticallyillwithintraabdominalinfections
AT uedatakashi isfixedshortcourseantimicrobialtherapyjustifiedforpatientswhoarecriticallyillwithintraabdominalinfections
AT nakajimakazuhiko isfixedshortcourseantimicrobialtherapyjustifiedforpatientswhoarecriticallyillwithintraabdominalinfections